Bora Biologics Expands San Diego CDMO Facility with Two 2000L Bioreactors

• Bora Biologics is expanding its San Diego CDMO facility by 8,075 sq ft to include new 2000L single-use bioreactors.

• The expansion enhances upstream and downstream GMP processing and is scheduled for completion by Q1 2026.

Bora Biologics, a contract development and manufacturing organization (CDMO) specialising in biologics, has announced a major expansion of its US FDA-registered commercial manufacturing facility in San Diego. The development adds 8,075 square feet of GMP manufacturing space, supporting 2000L single-use biologics manufacturing.

The expansion includes two new Cytiva XDR 2000L bioreactors and a full suite of upstream and downstream processing areas. This includes a mammalian cell culture hall, inoculation rooms, in-process testing room, capture suite, and downstream purification suite. The facility will accommodate future bioreactor expansion up to 5000L.

Construction comprises 6,950 sq ft of new space and 1,125 sq ft of modifications to existing GMP areas. Once operational in Q1 2026, the upgraded facility will offer robust scale-up and commercial manufacturing capabilities, complementing Bora’s current 50L to 1000L mammalian bioreactors and microbial systems.

“With this expansion, we will be able to offer our customers 2000L commercial capacity with the ability to purify modern high-titer cell culture processes,” said John R. Mosack, General Manager & Vice President, Operations of the San Diego Site at Bora Biologics.

Project partners include Cytiva, cGMPnow, and DPR Construction. Bora Biologics’ move reflects growing demand for flexible, large-scale biologics manufacturing in the CDMO sector.